  |
|
| 08.30-10.00 |
Faces in the Crowd: Emerging Strategies to Find and Treat Osteoporosis
Patients at High Risk of Fracture
Breakfast Symposium sponsored by NYCOMED |
| 10.00-11.45 |
SESSION III
Chairmen: D. FELSENBERG & I. MARTON |
10.00-10.30
PL3 |
Invited Lecture
Update on the Fracture Risk Assessment: Clinical and Economic Aspects
J. KANIS |
| 10.30-11.45 |
Oral Communications of selected abstracts |
10:30-10:40
OC22 |
MAGNITUDE AND DURATION OF EXCESS MORTALITY FOLLOWING HIP FRACTURE AMONG POSTMENOPAUSAL WOMEN: A META-ANALYSIS
P. Haentjens, D. Vanderschueren, K. Venken, S. Boonen |
10:40-10:50
OC23 |
ASSOCIATIONS BETWEEN INCREASE IN BONE MINERAL DENSITY AND DECREASE IN CLINICAL VERTEBRAL FRACTURE INCIDENCE DURING A TREATMENT WITH STRONTIUM RANELATE
O. Bruyère, C. Roux, J.B. Cannata, R. Rizzoli, K. Brixen, M.L. Brandi, J.-Y. Reginster |
10:50-11:00
OC24 |
TERIPARATIDE-MEDIATED CHANGES IN BONE MINERAL DENSITY (BMD) AND FRACTURE RISK REDUCTION IN WOMEN WITH
OSTEOPOROSIS
P. Chen, P. Miller, P.D. Delmas, D.A. Misurski, J. Krege |
11:00-11:10
OC25 |
A COMPARISON OF BONE MINERAL MEASUREMENTS FOR FRACTURE PREDICTION: A META-ANALYSIS
J.A. Kanis, O. Johnell, H. Johansson, A. Oden, P.D. Delmas, J.A. Eisman, S. Fujiwara, C. Gluer, H. Kroger, E.V. McCloskey, D. Melstrom, L.J. Melton III, H.A. Pols, J. Reeve, A. Silman, A. Tenenhouse |
11:10-11:20
OC26 |
EFFECTS OF GLUCOSAMINE SULFATE ON 6-MONTH CONTROL OF KNEE OSTEOARTHRITIS SYMPTOMS VS PLACEBO AND ACETAMINOPHEN: RESULTS FROM THE GLUCOSAMINE UNUM IN DIE EFFICACY (GUIDE) TRIAL
G. Herrero-Beaumont, J.A. Román, M.C. Trabado, F.J. Blanco, P. Benito, E. Martin-Mola, J. Paulino, J.L. Marenco, A. Porto, A. Laffon, D. Araùjo, M. Figueroa, J. Branco |
11:20-11:30
OC27 |
EFFECTS OF PARATHYROID HORMONE 1-84 ON CORTICAL AND TRABECULAR BONE AT THE HIP AS ASSESSED BY QCT: RESULTS AT 18 MONTHS FROM THE TOP STUDY
C.E. Bogado, J.R. Zanchetta, A. Mango, A.L. Mathisen, J. Fox |
11:30-11:40
OC28 |
EFFECT OF A ONCE-WEEKLY TABLET CONTAINING ALENDRONATE AND VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS
K. Lippuner, N. Binkley, P.D. Delmas, R. Recker, J. Ringe, J. Reed, D. Felsenberg, G. Salzmann, M. Liu, A. Santora |
| 12.15-13.45 |
Osteoporosis Patients: The Need for Complete Fracture Protection
Lunch Symposium sponsored by ALLIANCE FOR BETTER BONE HEALTH (PROCTER & GAMBLE
PHARMACEUTICALS AND SANOFI-AVENTIS) |
| 13.45-15.00 |
Poster Viewing and Visit of the Exhibition
Poster P200 to P299 |
| 15.00-16.45 |
SESSION IV
Chairmen: J. COMPSTON & U. A. LIBERMAN |
15.00-15.30
PL4 |
Invited Lecture
Update on the Management of Secondary Osteoporosis: Clinical and Economic Aspects
S. PAPAPOULOS |
| 15.30-16.45 |
Oral Communications of selected abstracts |
15:30-15:40
OC29 |
ARTICULAR CARTILAGE VOLUME AND THICKNESS MEASUREMENTS CORRELATE WITH PAIN AND FUNCTION IN INDIVIDUALS WITH MEDIAL TIBIOFEMORAL KNEE OA
K. Beattie, P. Boulos, D. Inglis, C. Webber, F. Eckstein, J.D. Adachi |
15:40-15:50
OC30 |
IBANDRONATE IS COST-EFFECTIVE IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS: A COMPARISION OF BISPHOSPHONATES
N.O. Lynch, S.R. Earnshaw, S. Beard, W. Cowell |
15:50-16:00
OC31 |
STRONTIUM RANELATE: AN ANTI-OSTEOPOROTIC TREATMENT DEMONSTRATED VERTEBRAL AND NONVERTEBRAL ANTI
FRACTURE EFFICACY OVER 5 YEARS IN POST MENOPAUSAL OSTEOPOROTIC WOMEN
J.-Y. Reginster, P.J. Meunier, C. Roux, J. Compston, S. Ortolani |
16:00-16:10
OC32 |
PRONOUNCED INCREASES IN BONE MINERAL DENSITY WITH INTERMITTENT INTRAVENOUS IBANDRONATE INJECTIONS: 2-YEAR RESULTS FROM DIVA
P.D. Delmas, J.A. Eisman, J. Stepan, C. Hughes, N. Mairon, D. Masanauskaite, D. Felsenberg |
16:10-16:20
OC33 |
PERSISTENCE WITH RISEDRONATE THERAPY IS ALREADY HIGH AND FURTHER IMPROVED BY A PATIENT EDUCATIONAL PROGRAM
P. Hadji, V. Ziller, M. Hartmann, B. Niggeschulze, S. Kroder, W. Möhrke |
16:20-16:30
OC34 |
TRABECULAR NUMBER AS A RISK FACTOR IN OSTEOPOROSIS AND THE ROLE OF NASAL SPRAY CALCITONIN (NS-CT) IN ITS MODIFICATION
M. Olson, L. Mindeholm, E.F. Eriksen, S. Majumdar, M. Azria, C. Chesnut |
16:30-16:40
OC35 |
EFFECT OF GLUCOSAMINE SULFATE ON NEWLY PROPOSED/RECOMMENDED CLINICAL TRIAL END-POINTS IN PATIENTS WITH KNEE OSTEOARTHRITIS
O. Bruyère, G. Giacovelli, K. Pavelka, L.C. Rovati, J.-Y. Reginster |
| 17.00-18.30 |
A New Approach for Improving Bone Health
Symposium sponsored by NOVARTIS PHARMA AG |
| 18.45-20.15 |
The RANK/RANKL/OPG pathway: From bench to clinical development
Symposium sponsored by AMGEN |
 
|
|
|